HPV Incidence, Clearance in Men Linked to Sexual BehaviorLast Updated: March 01, 2011. Incidence and clearance of genital human papillomavirus infection in men are strongly associated with sexual behavior, according to a study published online March 1 in The Lancet.
TUESDAY, March 1 (HealthDay News) -- Incidence and clearance of genital human papillomavirus (HPV) infection in men are strongly associated with sexual behavior, according to a study published online March 1 in The Lancet.
Anna R. Giuliano, Ph.D., from the H. Lee Moffitt Cancer Center in Tampa, Fla., and colleagues estimated the incidence and clearance of type-specific genital HPV infection in 1,159 men, aged 18 to 70, from Brazil, Mexico, and the United States, who were HIV negative and had no cancer history. Participants were assessed every six months for an average of 27.5 months. HPV genotypes status was assessed from glans penis, coronal sulcus, shaft, and scrotum specimens.
The investigators found that new genital HPV infection incidence was 38.4 per 1,000 person months. Average duration of any HPV infection was 7.52 months and 12.19 months for HPV 16. Oncogenic HPV infection was significantly higher in men who had 50 or more female partners compared to not more than one partner (hazard ratio [HR], 2.40) and in men who had at least three male anal sex partners compared with no recent partners (HR, 2.57). Clearance of oncogenic HPV infection was quicker with increasing age (HR, 1.02), and decreased in men with more female partners (HR, 0.49) and those in Brazil (HR, 0.71) or Mexico (HR, 0.73), compared to the United States.
"The results from this study provide much needed data about the incidence and clearance of HPV infection in men; these data are essential for the development of realistic cost-effectiveness models for male HPV vaccination internationally," the authors write.
Two study authors disclosed financial relationships with Merck, the manufacturer of the HPV vaccine.
|Previous: Helmets Protect Motorcyclists From Cervical Spine Injury||Next: Opioid Treatment Associated With Cognitive Dysfunction|
Reader comments on this article are listed below. Review our comments policy.